Orphalan
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
226 Boulevard Voltaire, Paris, Ile-de-Fr...Phone Number
+33 142498264Website
www.orphalan.comRevenue
$33.8 MillionIndustry
About Orphalan
Orphalan Org Chart
Is Orphalan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Orphalan launches new products
Congratulate Masked Content for being promoted to Masked Content at Orphalan
Funding: Get notified immidiatlly once Orphalan has new funding data
Website visits: Recent activity has been detected on your website
Orphalan, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Orphalan had a recent Job posting/layoffs
Earning: See what the market has to say on Orphalan recently announced quarterly report
Check out if Orphalan is spiking on competitors!
Check if Orphalan has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Orphalan as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Orphalan is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orphalan is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orphalan.
Orphalan Tech Stack
A closer look at the technologies used by Orphalan
Most Recent Scoops
Orphalan News & Media
Orphalan Initiates Global Phase 3 TRADITiONAL Study of Investigational Once-Daily Trientine Therapy in Wilson Disease
Phase 3 study will evaluate safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine as first line treatment in patients with Wilson disease. CHICAGO, Sept. 8, 2026 /PRNewswire/ -- Orphalan Inc. today announced the launch...Orphalan announces acquisition of Orphelia Pharma
PARIS, Dec. 12, 2025 /PRNewswire/ -- Orphalan, an international pharmaceutical company specializing in the development and commercialization of orphan drugs, has acquired Orphelia Pharma, a company committed to treating rare and severe pediatric diseases, notably in neurology and oncology....Orphalan becomes the first European company to enter in China's Wilson Disease market
Strategic partnership with Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd ("SPH Kyuan Trade") to transform access to Wilson's disease treatment for Chinese patients PARIS, March 7, 2025 /PRNewswire/ -- Orphalan, a global pioneer in orphan drug development and commercialization,...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orphalan
Orphalan SA is dedicated to developing innovative treatments for patients with rare diseases, particularly focusing on Wilson disease. The company aims to improve patient care and quality of life by providing access to effective therapies. With a presence in over 30 countries, Orphalan collaborates with the medical community to ensure that patients... Read More